Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer - PubMed (original) (raw)
Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer
Michael P Keane et al. J Immunol. 2004.
Abstract
The Glu-Leu-Arg(+) (ELR(+)) CXC chemokines are potent promoters of angiogenesis and have been demonstrated to induce a significant portion of nonsmall cell lung cancer-derived angiogenic activity and support tumorigenesis. ELR(+) CXC chemokines share a common chemokine receptor, CXCR2. We hypothesized that CXCR2 mediates the proangiogenic effects of ELR(+) CXC chemokines during tumorigenesis. To test this postulate, we used syngeneic murine Lewis lung cancer (LLC; 3LL, H-2(b)) heterotopic and orthotopic tumor model systems in C57BL/6 mice replete (CXCR2(+/+)) and deficient in CXCR2 (CXCR2(-/-)). We first demonstrated a correlation of the expression of endogenous ELR(+) CXC chemokines with tumor growth and metastatic potential of LLC tumors. Next, we found that LLC primary tumors were significantly reduced in growth in CXCR2(-/-) mice. Moreover, we found a marked reduction in the spontaneous metastases of heterotopic tumors to the lungs of CXCR2(-/-) mice. Morphometric analysis of the primary tumors in CXCR2(-/-) mice demonstrated increased necrosis and reduced vascular density. These findings were further confirmed in CXCR2(+/+) mice using specific neutralizing Abs to CXCR2. The results of these studies support the notion that CXCR2 mediates the angiogenic activity of ELR(+) CXC chemokines in a preclinical model of lung cancer.
Similar articles
- The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.
Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. Addison CL, et al. J Immunol. 2000 Nov 1;165(9):5269-77. doi: 10.4049/jimmunol.165.9.5269. J Immunol. 2000. PMID: 11046061 - CXCR2 is critical to hyperoxia-induced lung injury.
Sue RD, Belperio JA, Burdick MD, Murray LA, Xue YY, Dy MC, Kwon JJ, Keane MP, Strieter RM. Sue RD, et al. J Immunol. 2004 Mar 15;172(6):3860-8. doi: 10.4049/jimmunol.172.6.3860. J Immunol. 2004. PMID: 15004193 - The chemokine receptor, CXCR2, mediates the tumorigenic effects of ELR+ CXC chemokines.
Keane MP, Burdick MD, Xue YY, Lutz M, Belperio JA, Strieter RM. Keane MP, et al. Chest. 2004 May;125(5 Suppl):133S. doi: 10.1378/chest.125.5_suppl.133s. Chest. 2004. PMID: 15136463 No abstract available. - CXC chemokines in angiogenesis relevant to chronic fibroproliferation.
Strieter RM, Belperio JA, Burdick MD, Keane MP. Strieter RM, et al. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):23-6. doi: 10.2174/1568010053622902. Curr Drug Targets Inflamm Allergy. 2005. PMID: 15720231 Review. - Role of C-X-C chemokines as regulators of angiogenesis in lung cancer.
Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL. Strieter RM, et al. J Leukoc Biol. 1995 May;57(5):752-62. doi: 10.1002/jlb.57.5.752. J Leukoc Biol. 1995. PMID: 7539029 Review.
Cited by
- Characterization of the role of Samsn1 loss in multiple myeloma development.
Friend NL, Hewett DR, Panagopoulos V, Noll JE, Vandyke K, Mrozik KM, Fitter S, Zannettino ACW. Friend NL, et al. FASEB Bioadv. 2020 Aug 5;2(9):554-572. doi: 10.1096/fba.2020-00027. eCollection 2020 Sep. FASEB Bioadv. 2020. PMID: 32923989 Free PMC article. - Antitumor and Radiosensitization Effects of a CXCR2 Inhibitor in Nasopharyngeal Carcinoma.
Liu X, Lan T, Mo F, Yang J, Wei Y, Wei X. Liu X, et al. Front Cell Dev Biol. 2021 May 26;9:689613. doi: 10.3389/fcell.2021.689613. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34124076 Free PMC article. - Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2.
Dwyer J, Hebda JK, Le Guelte A, Galan-Moya EM, Smith SS, Azzi S, Bidere N, Gavard J. Dwyer J, et al. PLoS One. 2012;7(9):e45562. doi: 10.1371/journal.pone.0045562. Epub 2012 Sep 20. PLoS One. 2012. PMID: 23029099 Free PMC article. - Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
Davis RJ, Van Waes C, Allen CT. Davis RJ, et al. Oral Oncol. 2016 Jul;58:59-70. doi: 10.1016/j.oraloncology.2016.05.002. Epub 2016 May 20. Oral Oncol. 2016. PMID: 27215705 Free PMC article. Review. - Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, Ono M. Nakao S, et al. J Clin Invest. 2005 Nov;115(11):2979-91. doi: 10.1172/JCI23298. Epub 2005 Oct 20. J Clin Invest. 2005. PMID: 16239969 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA87879/CA/NCI NIH HHS/United States
- HL03906/HL/NHLBI NIH HHS/United States
- HL04493/HL/NHLBI NIH HHS/United States
- HL66027/HL/NHLBI NIH HHS/United States
- P50CA90388/CA/NCI NIH HHS/United States
- P50HL67665/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials